Cluster of differentiation antigen 135 (CD135) also known as fms like tyrosine kinase 3 (FLT-3 with fms standing for "feline McDonough sarcoma"), receptor-type tyrosine-protein kinase FLT3, or fetal liver kinase-2 (Flk2) is a protein that in humans is encoded by the FLT3 gene.

Mutations in FLT3 are the most common genetic alteration in AML, identified in approximately one third of newly diagnosed patients. FLT3 internal tandem duplication mutations (FLT3- ITD) are associated with increased relapse and inferior overall survival.

Mar 29, 2022 · FLT3 is the most common genetic change in acute myeloid leukemia (AML). Learn how new drugs are improving the outlook for people with the FLT3 mutation.

Oct 11, 2023 · What is an FLT3 mutation? An FLT3 mutation is the most common genetic mutation in AML. Experts estimate that around 33% of people with AML have an FLT3 mutation. The FLT3 gene manages the...

The FLT3 gene provides instructions for making a protein called fms-like tyrosine kinase 3 (FLT3), which is part of a family of proteins called receptor tyrosine kinases (RTKs). Learn about this gene and related health conditions.

Mar 30, 2025 · Complete information for FLT3 gene (Protein Coding), Fms Related Receptor Tyrosine Kinase 3, including: function, proteins, disorders, pathways, orthologs, and expression. GeneCards - The Human Gene Compendium

Sep 1, 2002 · FLT3 is a receptor tyrosine kinase expressed by immature hematopoietic cells and is important for the normal development of stem cells and the immune system.

Dec 23, 2020 · Mutations in FLT3 are the most common genetic alteration in AML, identified in approximately one third of newly diagnosed patients. FLT3 internal tandem duplication mutations (FLT3- ITD) are associated with increased relapse and inferior overall survival.

FMS‐like tyrosine kinase 3 (FLT3) is a type III receptor tyrosine kinase that plays an important role in hematopoietic cell survival, proliferation and differentiation. The most clinically important point is that mutation of the FLT3 gene is the most frequent genetic alteration and a poor prognostic factor in acute myeloid leukemia (AML) patients.

Mutations within the FMS-like tyrosine kinase 3 (FLT3) gene represent one of the most frequently identified genetic alterations that disturb intracellular signaling networks with a role in leukemia pathogenesis.